The technical architecture of the MyD88 pathway explains why it carries such weight. Toll-like receptors are pattern recognition receptors that detect pathogen-associated molecular patterns and damage-associated molecular patterns. Humans possess ten TLRs and mice twelve, distributed between the cell membrane and intracellular organelles. Structurally, TLRs are type I transmembrane proteins with an extracellular leucine-rich domain, a transmembrane segment, and an intracellular Toll/IL-1 receptor (TIR) domain. When a ligand engages the receptor, the TIR domain changes conformation and recruits MyD88, whose own C-terminal TIR domain forms heterodimers with the receptor and homodimerizes with itself, a step considered critical for signal transduction. The sole exception is TLR3, which signals independently of MyD88 through the TRIF adaptor. MyD88’s N-terminal death domain then attracts the kinases IRAK1 and IRAK4; IRAK4 phosphorylates IRAK1, which activates TRAF6 and, in turn, the NF-κB, MAPK, and PI3K-Akt cascades.

Nowhere is the oncogenic potential of this pathway clearer than in hematologic malignancy. The missense mutation L265P, which swaps a leucine for a proline at position 265 of MyD88, is found in roughly 90 percent of cases of Waldenström’s macroglobulinemia (WM), as well as in a large proportion of activated diffuse large B-cell lymphoma and IgM monoclonal gammopathy of undetermined significance. The review emphasizes how unusual this is in cancer: a single amino acid change acting as a dominant driver of disease, making WM a paradigm for treating disorders caused by one genetic alteration. Mechanistically, the L265P mutation renders the TIR domain hyperactive, strengthening binding to IRAK4 and phosphorylated IRAK1 so that the myddosome complex assembles even without external stimuli. The result is constitutive NF-κB signaling that sustains the survival and proliferation of malignant B cells.

The mutation also rewires cooperating pathways. In WM cells carrying L265P, MyD88 complexes with phosphorylated Bruton’s tyrosine kinase (pBTK) within the B-cell receptor signaling cascade, and disrupting this complex triggers apoptosis. MyD88 additionally activates transcription of the hematopoietic cell kinase HCK through NF-κB, and reducing HCK diminishes WM cell survival. Phelan and colleagues identified a MyD88-TLR9-BCR super-complex that engages the mTOR and CBM complexes to promote lymphomagenesis. Downstream, the pathway triggers autocrine IL-6 and IL-10 signaling, which phosphorylates JAK1 and then STAT3; STAT3 enhances expression of NF-κB, PI3K-AKT-mTORC1, and cell cycle checkpoint genes while suppressing interferon signaling components such as IRF7, IRF9, STAT1, and STAT2. Notably, selective IRAK1 and IRAK4 inhibitors killed ABC-DLBCL cells but promoted survival in GCB-DLBCL and myeloma lines, underscoring the context dependence of pathway targeting.

These insights are already shaping therapy. Although no drug directly approved against MyD88 exists for WM, the current frontline agent is the BTK inhibitor ibrutinib, and patients with MyD88 mutations respond exceptionally well: nearly all, 97.2 percent, achieve a major response, a phenomenon the authors attribute to MyD88’s involvement in B-cell receptor signaling. Combining BTK and IRAK inhibition is a plausible future strategy, and the review suggests that MyD88 itself remains a significant therapeutic target under active investigation.

In solid tumors, the story stretches back to Rudolf Virchow’s nineteenth-century observation linking inflammation to tumor growth. Chronic inflammation promotes cancer by augmenting DNA damage, driving tissue remodeling, secreting growth factors, and enhancing angiogenesis, and MyD88 sits at the center of these processes through its role in inflammation and the tumor microenvironment. In colitis-associated colorectal cancer, work in APC(Min/+) mice showed that MyD88 phosphorylates c-Myc via the ERK pathway, preventing its ubiquitination and proteasomal degradation; mice lacking MyD88 developed fewer and smaller tumors. MyD88-deficient myofibroblasts rendered mice resistant to AOM/DSS-induced tumorigenesis, partly by preventing macrophage M2 polarization through STAT3 and PPARγ signaling, and MyD88 inhibitors have been shown to curb both local and systemic inflammation while suppressing ERK signaling in intestinal epithelial cells.

The liver offers a parallel narrative. Human hepatocellular carcinoma tissues express higher levels of MyD88 than normal liver, and the adaptor activates PI3K-Akt signaling and accelerates epithelial-mesenchymal transition, promoting proliferation and metastasis. Knocking down the chemokine receptor CXCR3 reduces MyD88 expression, inhibiting cell proliferation and migration and slowing progression from fibrosis to cancer, while silencing MyD88 with siRNA impedes tumor cell growth. MyD88 also promotes non-alcoholic fatty liver-related hepatocarcinogenesis by fostering M2 macrophage polarization. In gastric cancer, the TLR2/MyD88 axis drives tumor cell stemness within the inflammatory microenvironment created by Helicobacter pylori infection, with TLR2 simultaneously inducing cytokines such as TNF-α and GM-CSF while suppressing the chemokines CXCL1 and CXCL8. In skin carcinogenesis, MyD88-dependent NF-κB activation is required for the pro-inflammatory response of oncogenic RAS in keratinocytes, and TLR4, activated by high mobility group box-1 protein, accelerates melanoma progression. In pancreatic cancer, TLR7/MyD88 signaling activates STAT3, NF-κB, and MAPK to promote tumor initiation, and MyD88 blockade dramatically ameliorated cachexia-associated anorexia, fatigue, and muscle wasting in models of pancreatic ductal adenocarcinoma.

Yet the review’s most provocative theme is that MyD88 is a double-edged sword. In some settings, its absence worsens disease. In DSS-induced colitis, MyD88 in macrophages maintains intestinal homeostasis; its deficiency upregulates S100A8, activating the NLRP3 inflammasome and pyroptosis in epithelial cells via a RAGE-dependent pathway. MyD88 knockout mice are more susceptible to AOM/DSS-induced colitis-associated cancer, partly because IL-18 receptor signaling, which regulates dendritic cells and IL-22-binding protein secretion by Th17 and Th22 cells, depends on MyD88 to drive epithelial repair. In the authors’ own experiments, systemic MyD88 inhibition accelerated the growth of established H22 liver tumors, and H22 cells implanted in MyD88 knockout mice grew faster than in wild-type animals, indicating that MyD88-mediated anti-tumor inflammation is essential once cancer has taken hold. Similar protective roles for TLR4 have been reported in DMBA-induced skin and breast cancer models.

The authors conclude that timing, location, duration, dosage, and formulation of any MyD88 intervention may determine whether the outcome is protective or harmful, since inhibiting the adaptor can simultaneously weaken immune surveillance against tumor cells and relieve inflammation-driven tumorigenesis. Drug development faces further hurdles: many candidate MyD88 inhibitors suffer from low bioavailability, short half-lives, and poor pharmacokinetics, and clinical trials remain scarce, with most evidence drawn from animal studies. Encouragingly, the inhibitor TJ-M2010-6 produced no significant weight loss or increased infection rates in mice. As the first example of a malignancy driven by a single dominant mutation, Waldenström’s macroglobulinemia demonstrates how targeting the MyD88 axis, directly or through partners such as BTK, can yield striking clinical benefit. The review argues that integrating MyD88-targeted therapy with immunotherapeutic approaches could reshape cancer treatment, provided researchers can resolve the biphasic biology of this indispensable, and occasionally dangerous, immune adaptor.

Subject of Research: The role of the MyD88 adaptor protein in tumor initiation and progression

Article Title: MyD88's function in the emergence and growth of tumors

Article References: Liu, J., Zhu, S., Huang, Q., Yao, Y., Li, W., & Zhang, S. (2024). MyD88's function in the emergence and growth of tumors. Clinical Cancer Bulletin, 3(1), Article 19. https://doi.org/10.1007/s44272-024-00023-x

Image Credits: AI Generated

DOI: 10.1007/s44272-024-00023-x

Keywords: MyD88, Toll-like receptors, NF-κB, Waldenström's macroglobulinemia, MYD88 L265P, colorectal cancer, hepatocellular carcinoma, inflammation, tumor microenvironment, BTK inhibitor, IRAK4, cancer immunotherapy

Understanding why sibling clusters matter requires a close look at what the disease actually is. Waldenström’s macroglobulinemia is a form of lymphoplasmacytic lymphoma, a slow-growing malignancy in which B lymphocytes — the immune system’s antibody-producing cells — transform and accumulate in the bone marrow, maturing into plasmacytoid cells that pump out enormous quantities of a single, identical immunoglobulin M molecule. IgM is the largest antibody in human circulation, a pentameric protein of roughly 970 kilodaltons, and because it is confined largely to the bloodstream, its overproduction physically thickens the blood. The result can be hyperviscosity syndrome, in which sludged circulation produces blurred vision, retinal hemorrhages, headaches, mucosal bleeding, and crushing fatigue, alongside anemia from marrow overcrowding, nerve damage, and — rarely — invasion of the central nervous system known as Bing-Neel syndrome. At the molecular level, more than 90 percent of cases carry a mutation called MYD88 L265P, which traps a pro-survival signaling cascade involving the transcription factor NF-κB in the on position, allowing malignant cells to ignore the apoptotic signals that would normally eliminate them. The disease typically announces itself in the mid-sixties or later, with fatigue and nonspecific symptoms that can delay diagnosis for years.

Against that backdrop, the Yancheng series is notable. The hematology team, whose corresponding author is Yuexin Cheng, combed a quarter century of institutional records and found that the earliest sibling pair had been diagnosed in 2002 and 2005 respectively, while the most recent pair was confirmed as late as 2022 — evidence that the phenomenon spans multiple diagnostic eras rather than belonging to any single moment. Men dominated the cohort, accounting for 90 percent of the ten cases, and the median age at diagnosis was 65.5 years, with a spread from 51 to 71. Those figures echo the classic profile of sporadic Waldenström’s macroglobulinemia, which favors older adults and shows a mild male predominance, but five pairs emerging from one hospital’s catchment area is striking for a disease this rare, and hints at how many familial clusters may be passing unnoticed in ordinary clinical practice.

Treatment patterns told a story of shifting therapeutic generations. Three patients received rituximab-based immunochemotherapy, regimens that pair rituximab — a monoclonal antibody engineered to latch onto the CD20 molecule decorating B-cell surfaces and recruit the immune system to destroy those cells — with cytotoxic chemotherapy. Five others were treated with combinations built on nucleoside analogs and alkylating drugs, older agents that damage DNA and predate the antibody era. As of December 2024, three patients had died of severe infection and one had died of traumatic injury. The infection toll is a sober reminder of the disease’s double vulnerability: the malignant clone crowds out the normal plasma cells that manufacture protective polyclonal antibodies, while chemotherapy compounds the immune deficit, leaving patients exposed to bacterial and opportunistic pathogens that healthy immune systems repel without difficulty.

The study’s central analytical question was whether sibling cases are biologically distinct from sporadic ones. To answer it, the investigators placed familial and sporadic disease side by side across an unusually comprehensive battery of clinical and laboratory variables: sex and age at diagnosis; Eastern Cooperative Oncology Group performance status, a standard scale of functional fitness; B symptoms, the fevers, drenching night sweats, and unintentional weight loss that mark high disease activity; prior exposure to Bruton tyrosine kinase inhibitors, targeted drugs that block a signaling node downstream of MYD88; the International Prognostic Scoring System for Waldenström’s macroglobulinemia; hemoglobin, platelet count, lactate dehydrogenase, β2-microglobulin, serum IgM concentration, and albumin; enlargement of the liver or spleen; lymphadenopathy; and MYD88 L265P mutation status. On every measure, the sibling cases were indistinguishable from sporadic ones. No significant difference surfaced in any parameter, suggesting that whatever predisposes a family to this cancer does not produce a visibly more aggressive or atypical disease in the relatives who ultimately develop it.

One number, however, refused to behave. Median overall survival reached 230 months — more than nineteen years — among patients with familial disease, versus 96 months, or eight years, among those with sporadic Waldenström’s macroglobulinemia. Statistically the gap did not clear the bar of significance: the comparison yielded a p value of 0.2 and a hazard ratio of 0.6, with a 95 percent confidence interval stretching from 0.2 to 1, a range so wide it cannot exclude either no effect at all or a substantial survival advantage. With only ten familial patients, the finding is best read as a hypothesis generator rather than a conclusion. Familial cases might genuinely carry more indolent biology, shaped by germline variants that favor slower clonal expansion. Alternatively, the apparent benefit may be an artifact of detection: siblings of diagnosed patients are watched more closely, so their disease is caught earlier and at a lower tumor burden — a lead-time effect that lengthens measured survival without altering the disease’s underlying course.

The report lands amid mounting evidence that this cancer runs in families to a degree unusual even among hematologic malignancies. Family history of lymphoproliferative disease is a recognized risk factor, and by some estimates roughly one in five patients reports a close relative with Waldenström’s macroglobulinemia or another B-cell disorder. Genome-wide association studies have tied inherited variants scattered across several chromosomal regions to disease susceptibility, and the malignancy follows a recognizable precursor pathway: IgM monoclonal gammopathy of undetermined significance, or MGUS, a state in which a small clone secretes a monoclonal protein without yet causing symptoms, progresses to overt disease at a low but steady annual rate. Siblings share both genes and environments — households, diets, infections, occupational exposures — and disentangling the two is notoriously difficult. The Yancheng authors addressed that uncertainty in a practical way: their paper includes an overview of the screening initiatives their hospital applied to siblings of diagnosed patients, an approach designed to catch monoclonal IgM on routine laboratory testing before symptoms force the issue.

Arguably the most consequential sentence in the paper is among its quietest: the incidence of Waldenström’s macroglobulinemia in siblings in the real world may be underestimated. If familial clustering is more common than currently recognized, the practical consequences are tangible. A single family-history question at a first hematology consultation can flag at-risk relatives at essentially no cost. Periodic serum protein electrophoresis in siblings of diagnosed patients could surface IgM MGUS years before transformation, enabling surveillance and early intervention. Early detection matters beyond statistics: hyperviscosity crises demand urgent plasmapheresis, a procedure that mechanically filters thickened plasma to strip away excess IgM, and retinal, neurologic, and bleeding complications can become irreversible when the diagnosis arrives late. Catching a rising monoclonal IgM in a symptomless sibling converts an emergency-medicine problem into a monitored outpatient one — a shift that, in a disease whose treatments grow steadily more effective, may help explain survival gaps like the one the Yancheng data hinted at.

The authors are candid about the study’s boundaries. Ten patients at a single center cannot settle questions of genetic architecture; no germline sequencing was performed, so shared inherited variants cannot be separated from shared environments, and the survival comparison is powered for hypotheses rather than definitive claims. What the series does establish is that familial Waldenström’s macroglobulinemia is not vanishingly rare in everyday hematology practice, that its clinical and laboratory face is unremarkable, and that deliberate screening within families can surface cases that would otherwise scatter silently across decades. The work was supported by the Yancheng Municipal Health Commission and by open research projects in key laboratories of Jiangsu universities, and it arrives as the therapeutic landscape shifts again, with Bruton tyrosine kinase inhibitors now interrupting the very MYD88-driven pathway that fuels the disease. Longer follow-up and multicenter registries will need to test whether the familial survival trend survives contact with larger numbers. For now, the message to clinicians is simpler: ask patients about their siblings, then check the IgM.